The Most Common MPN Symptoms Patients Should Never Ignore

A landmark 2025 German study of nearly 4,000 MPN patients found that physicians consistently documented fewer and less severe symptoms than patients actually reported. MPN symptoms like fatigue, night sweats, and itching were frequently missed—and patients with severe symptoms faced higher mortality rates. Better communication and standardized symptom tools are urgently needed.

Living with a myeloproliferative neoplasm (MPN) is not just about managing abnormal blood counts. For thousands of patients with polycythemia vera (PV), myelofibrosis (MF), or essential thrombocythemia (ET), the daily reality is far more exhausting—and far more painful—than what shows up in their medical records.

Now, a major new study has put hard numbers to something the MPN community has long suspected: there is a significant gap between what patients experience and what their doctors actually document. The findings are striking, and for those navigating life with an MPN diagnosis, they carry real weight.

Published in the journal Leukemia in 2025, research from the German Study Group for MPN (GSG-MPN) tracked nearly 4,000 MPN patients and compared patient-reported symptoms against physician-recorded assessments. What the data revealed is both validating for patients and sobering for the medical community.

What the Study Found About MPN Symptom Burden

The numbers tell a clear story. According to the study by Manz, Heidel, Koschmieder, et al. (2025), a striking 93% of patients reported experiencing at least one symptom. Fatigue was among the most commonly reported, followed by night sweats, itching, and weight loss.

Despite this, physicians consistently logged fewer symptoms—and rated those symptoms as less severe—than their patients did. The discrepancy was not minor. Patients described MPN symptoms that were significantly more disruptive to their daily lives than what appeared in their clinical notes.

Even more concerning: patients with severe symptom burdens had measurably higher death rates. This finding elevates the issue far beyond one of comfort or quality of life. Unrecognized and underdocumented MPN symptoms may have real consequences for patient survival.

Why Do Doctors Miss So Much?

There are a few reasons this gap exists, and most of them come down to structure and communication—not indifference.

The 15-Minute Appointment Problem

Most specialist appointments are short. In a rushed 15-to-20-minute visit, patients often downplay how they are truly feeling. A quick “I’m managing” can mask weeks of debilitating fatigue or persistent itching that disrupts sleep. Doctors, working through a packed schedule, may not probe deeply enough to uncover the full picture.

A Focus on Numbers Over Feelings

Hematology is, understandably, a numbers-driven specialty. Blood counts, platelet levels, and hematocrit values are measurable, trackable, and easy to compare over time. Subjective experiences—how exhausted a patient feels, how often night sweats wake them up—are harder to quantify, and they can get deprioritized as a result.

No Standardized Symptom Tracking

One of the most actionable findings from the study is that most physicians do not use standardized patient-reported outcome tools during appointments. Without a consistent framework for capturing MPN symptoms, each visit becomes a free-form conversation that can easily miss critical details. Tools like the MPN Symptom Assessment Form exist precisely to address this gap, and MPN specialists who use them routinely tend to capture a far more complete picture of how their patients are doing.

Does Treatment Actually Help With Symptoms?

This may be the most confronting part of the study’s findings. Patients receiving common MPN treatments—including hydroxyurea, interferon, and JAK inhibitors—did not report significantly fewer symptoms compared to untreated patients.

That raises an important question: are current treatment approaches too narrowly focused on normalizing blood counts, rather than improving how patients actually feel day to day? It does not mean these treatments are ineffective—many patients do experience meaningful relief—but the study suggests that symptom management deserves its own place at the treatment planning table, not just a footnote after the lab results are reviewed.

How Patients Can Advocate for Themselves

The research is clear that better documentation starts with better communication. While systemic changes in clinical practice take time, there are concrete steps MPN patients can take right now to make sure their full experience is heard and recorded.

Keep a symptom diary. Track how you feel between appointments—not just on good days, but on bad ones too. Note the frequency, duration, and severity of fatigue, itching, night sweats, abdominal discomfort, and any other symptoms. Patterns that emerge over weeks will tell a more complete story than what you can recall in the exam room.

Bring a written list to every appointment. Many patients find that arriving with a prepared list of questions and symptom updates leads to more productive visits. It signals to your care team that you are engaged, and it ensures nothing important gets left out.

Ask about patient-reported outcome tools. Specifically request that your care team incorporate a standardized symptom assessment form into your regular visits. The MPN Symptom Assessment Form is one widely recognized option. It creates a consistent, documented record of how your MPN symptoms are affecting your life over time.

Do not downplay how you feel. It can be tempting to minimize symptoms—especially when you want to seem like you are handling things well, or when you sense your doctor is pressed for time. Resist that impulse. Accurate reporting is not complaining. It is essential data.

What Needs to Change at the Clinical Level

Patient advocacy can only go so far. The study makes a compelling case that the medical system itself needs to evolve in how it approaches MPN symptom burden.

Standardized symptom assessment tools should become routine in MPN care, not optional extras. Treatment goals should be explicitly expanded to include quality-of-life outcomes alongside hematological markers. And appointment structures need to allow enough time for patients to report what they are genuinely experiencing.

The MPN community—patients, caregivers, researchers, and advocates—has long called for a more complete picture of what it means to live with these rare blood cancers. This study gives that call scientific backing.

The Bottom Line on MPN Symptoms and Patient Care

The 2025 GSG-MPN study confirms what many in the MPN community have felt for years. There is a real and consequential gap between the symptoms patients live with and what gets documented in their medical records. And given the link between severe MPN symptoms and higher mortality rates, closing that gap is not just a quality-of-life issue—it is a matter of survival.

Progress will require movement on both sides. Patients need to speak up more fully, armed with diaries, lists, and a willingness to push through the instinct to say “I’m fine.” Clinicians need better tools, more time, and a framework that treats symptom burden as seriously as blood count targets.

For anyone navigating life with an MPN diagnosis, resources like PV Reporter offer reliable, patient-centered information on treatment updates, symptom management, and community support. You do not have to piece this together alone—and you do not have to accept being unheard.

Frequently Asked Questions

What are the most common MPN symptoms reported by patients?
According to a 2025 study published in Leukemia, the most commonly reported MPN symptoms include fatigue, night sweats, itching (pruritus), and weight loss. Fatigue is particularly prevalent, with the majority of patients in the study reporting it as a significant burden.

Why do doctors underestimate MPN symptom severity?
Several factors contribute, including time-limited appointments, a clinical focus on measurable data like blood counts, and the absence of standardized symptom assessment tools. Patients also sometimes downplay their symptoms during visits, which compounds the documentation gap.

Does MPN treatment reduce symptoms?
The 2025 GSG-MPN study found that patients on treatments such as hydroxyurea, interferon, and JAK inhibitors did not report significantly fewer symptoms than untreated patients. This suggests that current treatments may prioritize hematological control over direct symptom relief, though individual experiences vary.

What is the MPN Symptom Assessment Form?
The MPN Symptom Assessment Form is a standardized tool designed to help patients and physicians systematically track and document symptom burden over time. Using it consistently at appointments can help ensure that MPN symptoms are accurately captured and inform treatment decisions.

Are severe MPN symptoms linked to worse health outcomes?
Yes. The 2025 study found that patients who reported severe symptom burdens had higher mortality rates, underscoring that symptom management is not a secondary concern—it has direct implications for patient survival.

Where can MPN patients find reliable information and support?
PV Reporter is a trusted, patient-founded resource dedicated to myeloproliferative neoplasms, offering educational content, patient stories, treatment updates, and community support for people living with PV, MF, and ET.